pharmaceutical-market-research-reports-isr-v1

PHARMACEUTICAL MARKET RESEARCH REPORTS

Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of BioProcess Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.

ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.

TRENDS AND MARKET OUTLOOKS

  • Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)

    This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.

  • Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)

    This market research report goes into depth on the manufacturing aspect of biosimilars. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom.

  • Biologic Sterile Injectable Drug Product Manufacturing Market Overview and Outlook
    Biologic Sterile Injectable Drug Product Manufacturing Market Overview and Outlook

    This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number...

  • Pharmaceutical Excipient Market Overview and Outlook
    Pharmaceutical Excipient Market Overview and Outlook

    This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.

  • Development vs Commercial Outsourced Manufacturing Practices: Biologics
    Development vs Commercial Outsourced Manufacturing Practices: Biologics

    This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.

  • Central Lab Market Dynamics and Outsourcing Performance (2019-2022)
    Central Lab Market Dynamics and Outsourcing Performance (2019-2022)

    This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.

QUALITY BENCHMARKING AND SERVICE PROVIDER PERFORMANCE

  • Bioanalytical Labs Market Dynamics and Service Provider Performance
    Bioanalytical Labs Market Dynamics and Service Provider Performance

    Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.

  • Biologic Drug Product Contract Manufacturer Quality Benchmarking
    Biologic Drug Product Contract Manufacturer Quality Benchmarking

    This report gives an-depth look at a subset of respondents from small and emerging biopharma companies. It will help small and emerging biopharmaceutical companies make more informed CMO decisions, and will help CMOs optimize operational and marketing strategies.

DEPARTMENT MODELS AND STRUCTURES

  • The CMC Function: Best Practices and Optimization
    The CMC Function: Best Practices and Optimization

    ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.

ISR ARTICLES

  • Reasons CDMOs Lose Sterile Injectable Manufacturing Bids

    In Q2 2019, ISR asked 101 respondents who outsource sterile injectable drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 25% of respondents’ votes..

  • Small And Emerging Biopharma Companies Outsourcing Practices

    There is no question that the drug development services industry is complex, dynamic, and continuously evolving. While every sponsor company is different, all can benefit from keeping a pulse on current outsourcing practices and the activities being outsourced. Over the past year, ISR conducted several research activities with the aim of better understanding the needs of small and emerging biopharma companies and how they differ from the larger industry players. This article highlights the results of this survey.

  • Reasons CDMOs Lose Bioprocessing Bids

    In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes.

  • Trends In Bioprocessing CDMO Selection

    Learn which CDMO characteristics experienced outsourcers value most from ISR’s Bioprocessing Market Trends and Outsourcing Dynamics report.

  • Small Molecule Drug Substance Outsourcing Drivers

    In Q4, 2019 ISR surveyed 42 outsourcers from small biopharma companies to find out how they would characterize their company’s main driver for working with CMOs on small molecule drug substance manufacturing work. The vast majority, 86%, reported using CMOs for all of their manufacturing needs. 

ABOUT ISR VIDEO